Pure CBD or Botanical Preparation

Cannabis montage

In an article published by Pharmacology &Pharmacy (Feb. 2015), a direct challenge an orthodoxy coveted by the medical world ,that “crude” or raw botanical preparations are of low grade and less effective than pure, single-molecule compounds.

"In the present study, we have studied in mice the anti‐inflammatory and anti‐nociceptive activities of standardized plant extracts derived from the Cannabis sativa L., clone 202, which is highly enriched in CBD and hardly contains any psychoactive ingredients. In stark contrast to purified CBD, the clone 202 extract, when given either intraperitoneally or orally, provided a clear correlation between the anti‐inflammatory and anti‐nociceptive responses and the dose, with increasing responses upon increasing doses, which makes this plant medicine ideal for clinical uses. The clone 202 extract reduced zymosan‐induced paw swelling and pain in mice, and prevented TNFα production in vivo. It is likely that other components in the extract synergize with CBD to achieve the desired anti‐inflammatory action that may contribute to overcoming the bell‐shaped dose‐response of purified CBD. We therefore propose that Cannabis clone 202 (Avi‐ dekel) extract is superior over CBD for the treatment of inflammatory conditions."

The Israeli team sought to determine whether the administration of a whole plant CBD-rich extract would also generate a bell-shaped dose-response curve when administered to mice. Or would cannabidiol extracted from CBD-rich Cannabis avoid this liability? “The aim of the present study,” the authors explained, “was to find a CBD source that could eliminate the bell-shaped dose-response of purified CBD.”

The pure CBD tests confirmed the findings of earlier preclinical research. Once again, single-molecule CBDadministration generated a bell-shaped dose-response curve with a narrow therapeutic window.

But a different dose response pattern was observed when the clone 202 extract was administered to mice. Rather than showing a bell-shaped curve, where a therapeutic effect could only be achieved at a certain concentration of pure CBD, the whole plant CBD-rich extract caused a direct, dose-dependent inhibition of pain, inflammation, and TNFa production. “In stark contrast to purified CBD,” the Israeli team reported, “the clone extract…provided a clear correlation between the anti-inflammatory and anti-nociceptive responses and the dose, with increasing responses upon increasing doses, which makes this plant medicine ideal for clinical uses.”

Moreover, the Israeli researchers found that a small amount of CBD in the clone extract was needed for significant pain relief compared to the much larger amount of pure CBD required to achieve the same analgesic effect. And whereas pure, single-molecule CBD precipitated a dramatic drop in efficacy if more than a specific dosage was administered, an “overdose” of whole plant CBD-rich extract did not undermine its therapeutic potency. When greater than an optimal dose of the clone 202 oil was administered, its effectiveness leveled off, suggesting that a medicinal plateau had been reached.

The Israeli study found that Cannabis clone 202 extract “is superior over CBD for the treatment of inflammatory conditions.” The greater efficiency of the whole plant extract might be explained by additive or synergistic interactions between CBD and dozens of minor phytocannabinoids and hundreds of non-cannabinoid plant compounds. “It is likely that other components in the extract synergize with CBD to achieve the desired anti-inflammatory action that may contribute to overcoming the bell-shaped dose-response of purified CBD,” the Israeli team surmised.

Link to original article where these excerpt where taken.